化合物T-1095 T9590

Product Introduction
Bioactivity


英文名: T-1095

描述: T-1095 是一种口服有活性的Na+-葡萄糖协同转运蛋白选择性抑制剂，能够抑制 SGLT1 (IC50:22.8 µm) 及 SGLT2 (IC50:2.3 µm) 。它可用于研究糖尿病。

体内活性: Administration of 0.03% and 0.1% (wt/wt diet) T-1095 to STZ rats for 4 weeks improved the hyperglycemia and dose-dependently decreased HbA1c[1]. Moreover, treatment with 0.1% (wt/wt diet) T-1095 in STZ rats for 8 weeks not only reduced blood glucose and HbA1c, levels but also prevented the elevation of urinary albumin levels and kidney weight and the development of epithelial vacuolation[1]. The expression of renal SGLT2, a major glucose transporter in the kidney, was not different in normal, STZ, and T-1095-treated STZ rats. In contrast, the elevated renal GLUT2 level in STZ rats was suppressed by T-1095[1].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 60 mg/mL (116.17 mM)


关键字: SGLT1 | Sodium-dependent glucose cotransporters | antidiabetic | SGLT2 | Inhibitor | orally active | T-1095 | SGLT | T1095 | inhibit | T 1095

相关产品: Ertugliflozin | SGL5213 | Kushenol C | Phlorizin | Mizagliflozin | O-Desethyl Dapagliflozin | HSK0935 | Empagliflozin | SGLT inhibitor-1 | Canagliflozin hemihydrate

相关库: ReFRAME Related Library | Membrane Protein-targeted Compound Library | Bioactive Compounds Library Max | Inhibitor Library | GPCR Compound Library | Anti-Diabetic Compound Library | Metabolism Compound Library | Orally Active Compound Library | Glycolysis Compound Library | Bioactive Compound Library

化合物T-1095 T9590信息由TargetMol中国为您提供，如您想了解更多关于化合物T-1095 T9590报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途